Wall Street analysts expect argenx SE – (NASDAQ:ARGX) to post ($0.90) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Five analysts have issued estimates for argenx’s earnings, with the lowest EPS estimate coming in at ($1.07) and the highest estimate coming in at ($0.74). The firm is scheduled to report its next earnings report on Monday, January 1st.
According to Zacks, analysts expect that argenx will report full-year earnings of ($2.69) per share for the current fiscal year, with EPS estimates ranging from ($3.05) to ($2.32). For the next financial year, analysts anticipate that the business will post earnings of ($4.77) per share, with EPS estimates ranging from ($5.79) to ($4.14). Zacks’ earnings per share averages are a mean average based on a survey of research firms that that provide coverage for argenx.
A number of brokerages have recently commented on ARGX. Robert W. Baird began coverage on argenx in a research report on Thursday, June 27th. They issued an “outperform” rating and a $170.00 price target on the stock. Zacks Investment Research cut argenx from a “buy” rating to a “hold” rating in a research report on Wednesday, June 26th. Stifel Nicolaus set a $154.00 price objective on argenx and gave the company a “buy” rating in a research report on Wednesday, May 22nd. Finally, Piper Jaffray Companies boosted their target price on shares of argenx from $161.00 to $182.00 and gave the company an “overweight” rating in a research note on Thursday, May 23rd. One investment analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. argenx has a consensus rating of “Buy” and an average target price of $149.91.
Large investors have recently bought and sold shares of the company. Marshall Wace LLP purchased a new stake in argenx in the 1st quarter worth $121,000. SG Americas Securities LLC purchased a new stake in argenx in the 1st quarter worth $134,000. Partner Investment Management L.P. purchased a new stake in argenx in the 4th quarter worth $110,000. Virtu Financial LLC purchased a new stake in argenx in the 1st quarter worth $217,000. Finally, NumerixS Investment Technologies Inc purchased a new stake in argenx in the 1st quarter worth $250,000. Hedge funds and other institutional investors own 68.04% of the company’s stock.
Shares of ARGX stock traded down $0.87 during midday trading on Friday, reaching $142.49. 341 shares of the stock were exchanged, compared to its average volume of 168,594. The company has a 50 day simple moving average of $130.94. argenx has a 1 year low of $63.81 and a 1 year high of $144.34. The firm has a market cap of $4.61 billion, a price-to-earnings ratio of -60.71 and a beta of 1.18.
argenx Company Profile
argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's lead product candidates include ARGX-113 that completed Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis, immune thrombocytopenia, and pemphigus vulgaris; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome.
Read More: Why is the ROA ratio important?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for argenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx and related companies with MarketBeat.com's FREE daily email newsletter.